November 30, 2023 07:08 AM EST
Financing
R&D

Xenon of­fers $300M in shares af­ter tout­ing path ahead for MDD pro­gram de­spite PhII miss

Ayisha Sharma

News Reporter

Xenon Phar­ma­ceu­ti­cals has an­nounced a pub­lic of­fer­ing of $300 mil­lion in shares just days af­ter it un­veiled mixed Phase II da­ta for its ma­jor de­pres­sive …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Jazz wins ap­proval for bis­pe­cif­ic in bil­iary tract can­cer

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

FDA ad­comm rais­es risk ques­tions on As­traZeneca’s An­dexxa

At Jef­feries, all that man­u­fac­tur­ers want to talk about is GLP-1s

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times